1-[[4-[3-[5-Chloro-2-fluoro-3-(methanesulfonamido)phenyl]-1-propan-2-ylpyrazol-4-yl]pyrimidin-2-yl]amino]propylcarbamic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-[[4-[3-[5-Chloro-2-fluoro-3-(methanesulfonamido)phenyl]-1-propan-2-ylpyrazol-4-yl]pyrimidin-2-yl]amino]propylcarbamic acid
• 英文别名: 1-[[4-[3-[5-chloro-2-fluoro-3-(methanesulfonamido)phenyl]-1-propan-2-ylpyrazol-4-yl]pyrimidin-2-yl]amino]propylcarbamic acid
• 化学式: C₂₁H₂₅ClFN₇O₄S
• 分子量: 526.0
• InChiKey: DNTPWMXDDDNZTM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  35
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  160
• 氢给体数：
  4
• 氢受体数：
  10

文献信息

• DNA hypomethylating agents for cancer therapy
  申请人：Maio Michele

  公开号：US11083743B2

  公开（公告）日：2021-08-10

  The present invention relates to a method of treating and/or preventing cancer comprising administering a combination of an effective amount of a DNA hypomethylating agent and an effective amount of at least one immunomodulatory agent and/or optionally an effective amount of at least one targeted therapy agent.

  本发明涉及一种治疗和/或预防癌症的方法，包括施用有效量的 DNA 低甲基化剂和有效量的至少一种免疫调节剂和/或有效量的至少一种靶向治疗剂的组合。
• Pharmaceutical combinations
  申请人：Array BioPharma Inc.

  公开号：US11376239B2

  公开（公告）日：2022-07-05

  Provided herein are pharmaceutical combinations comprising (a) a B-Raf inhibitor, or a pharmaceutically acceptable salt thereof, (b) at least one mitogen activated protein kinase (MEK) inhibitor, or a pharmaceutically acceptable salt thereof, and (c) an epidermal growth factor receptor (EGFR) inhibitor or a pharmaceutically acceptable salt thereof; and optionally at least one pharmaceutically acceptable carrier; methods for preparing the pharmaceutical combinations, and the uses of the pharmaceutical combinations in the treatment of proliferative diseases, such as cancer.

  本文提供的药物组合物包含：(a) B-Raf抑制剂或其药学上可接受的盐；(b) 至少一种丝裂原活化蛋白激酶（MEK）抑制剂或其药学上可接受的盐；(c) 表皮生长因子受体（EGFR）抑制剂或其药学上可接受的盐；以及任选的至少一种药学上可接受的载体；制备药物组合物的方法，以及药物组合物在治疗增殖性疾病（如癌症）中的用途。
• NOVEL FUSION MOLECULES AND USES THEREOF
  申请人：Foundation Medicine, Inc.

  公开号：EP2914622A2

  公开（公告）日：2015-09-09
• DNA HYPOMETHYLATING AGENTS FOR CANCER THERAPY
  申请人：Maio, Michele

  公开号：EP2958571A1

  公开（公告）日：2015-12-30
• Deuterium-enriched pyrimidine compounds and derivatives
  申请人：Dhanoa Daljit Singh

  公开号：US20110028496A1

  公开（公告）日：2011-02-03

  The present invention is concerned with deuterium-enriched pyrimidine compounds of formula I, their derivatives and pharmaceutically acceptable salts and methods of use thereof for the treatment of pulmonary arterial hypertension, pulmonary hypertension associated with chronic obstructive pulmonary disease (COPD), asthma, cystic fibrosis, hypertension, ischemic stroke, angina pectoris, congestive heart failure, arrhythmia, arterial fibrillation, Alzheimer's disease, cognition impairment, memory decline, and schizophrenia, and depression.